Nektar Therapeutics (NKTR) Prices 13M Common Stock Offering at $13.50/Share

October 19, 2016 6:12 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Nektar Therapeutics (Nasdaq: NKTR) announced the pricing of its previously announced underwritten public offering of $175.5 million in aggregate gross proceeds, or 13,000,000 shares of its common stock at a public offering price of $13.50 per share. In connection with this offering, Nektar has also granted to the underwriters a 30-day option to purchase up to an additional 1,950,000 shares of common stock at the offering price.

J.P. Morgan is acting as lead book-running manager in the offering. Jefferies and Piper Jaffray are acting as book-running managers. William Blair is acting as lead manager for the offering, and Brean Capital, BTIG, Janney Montgomery Scott, Ladenburg Thalmann and ROTH Capital Partners are acting as co-managers for the offering.

Nektar intends to use the net proceeds from this offering for general corporate purposes including research and development funding and working capital.

The securities described above are being offered by Nektar pursuant to an effective shelf registration statement, including a prospectus supplement and accompanying prospectus, copies of which may be obtained from the offices of J.P. Morgan Securities LLC, attention Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York, NY 11717, or telephone: 866-803-9204.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Equity Offerings

Related Entities

Piper Jaffray, William Blair, JPMorgan, Jefferies & Co, Roth Capital, Janney Montgomery Scott, Ladenburg Thalmann Financial Services, BTIG, Brean Capital

Add Your Comment